Vernalis Achieve Research Milestone in Drug Discovery Collaboration

Vernalis plc, today announces it has achieved a research milestone in its drug discovery collaboration with H.Lundbeck A/S (Lundbeck). As a result, Vernalis will receive a payment of £0.3m from Lundbeck in recognition of this achievement.

Under the terms of the collaboration which utilises Vernalis’ fragment and structure-based drug discovery platform against LRRK2, a kinase target, Vernalis will receive fees and a potential share in the downstream success of the product in the form of milestones and royalties on sales. The financial terms of this collaboration are not disclosed.

Ian Garland, CEO of Vernalis commented: “Achieving this milestone further validates the strength of our fragment and structure-based drug discovery platforms. We look forward to continued success in our collaboration with Lundbeck”.

Picture: the Vernalis Building on Granta Park